Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

Kathryn C Arbour^{1

2}, Piro Lito^{1

2

3}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Medicine, Weill Cornell Medical College, New York, NY.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY.

Comment

Kathryn C Arbour et al. J Clin Oncol. 2022.

. 2022 Aug 10;40(23):2609-2611.

doi: 10.1200/JCO.22.00562. Epub 2022 Jun 28.

Kathryn C Arbour^{1

2}, Piro Lito^{1

2

3}

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Medicine, Weill Cornell Medical College, New York, NY.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY.

No abstract available

Comment on

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1).
Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova L, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. Ou SI, et al. J Clin Oncol. 2022 Aug 10;40(23):2530-2538. doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15. J Clin Oncol. 2022. PMID: 35167329 Free PMC article. Clinical Trial.